Literature DB >> 24419758

Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage.

Mee Joo Kang1, Jin-Young Jang, Ye Rim Chang, Wooil Kwon, Woohyun Jung, Sun-Whe Kim.   

Abstract

BACKGROUND: Some suggest that metastatic lymph node ratio (LNR) may be prognostic of survival in patients with pancreatic cancer. However, this phenomenon was confused by inclusion of node-negative patients in the analysis. The present study was designed to evaluate the prognostic impact of metastatic LNR and the absolute number of metastatic LNs in patients resected for pancreatic cancer.
METHODS: Data were collected from 398 patients who underwent curative surgery for pancreatic head cancer at Seoul National University Hospital. Long-term survival was analyzed according to LNR and absolute number of metastatic LNs.
RESULTS: Of the patients, 227 (57.0 %) had LN metastasis. The mean numbers of total retrieved and metastatic LNs were 19.5 and 1.9, respectively, and the mean LNR was 0.11. Median overall survival (OS) of patients was significantly higher in N0 than in N1 patients after curative resection (25.4 vs. 14.8 months, p < 0.001). Median OS was significantly lower in patients with 1 than in those with 0 positive LNs (17.3 vs. 25.4 months, p = 0.001). Among N1 patients, those with 0 < LNR ≤ 0.2 had comparable prognosis than those with >0.2 LNR (median OS 17.2 vs. 12.8 months, p = 0.096), and the number of metastatic LNs did not correlate with median OS (p = 0.365).
CONCLUSIONS: The presence of a single positive metastatic LN was associated with significantly poorer OS in patients with pancreatic cancer. When LN metastasis was present, the number of metastatic LNs and LNR had limited prognostic relevance.

Entities:  

Mesh:

Year:  2014        PMID: 24419758     DOI: 10.1245/s10434-013-3473-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

1.  Neoadjuvant treatment for resectable pancreatic adenocarcinoma.

Authors:  John Wong; Naveenraj L Solomon; Chung-Tsen Hsueh
Journal:  World J Clin Oncol       Date:  2016-02-10

2.  A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer.

Authors:  Toshiro Masuda; Amanda M Dann; Irmina A Elliott; Hideo Baba; Stephen Kim; Alireza Sedarat; V Raman Muthusamy; Mark D Girgis; O Joe Hines; Howard A Reber; Timothy R Donahue
Journal:  J Gastrointest Surg       Date:  2017-10-17       Impact factor: 3.452

3.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.

Authors:  Yizhen Pang; Long Zhao; Qihang Shang; Tinghua Meng; Liang Zhao; Liuxing Feng; Shuangjia Wang; Ping Guo; Xiurong Wu; Qin Lin; Hua Wu; Weipeng Huang; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

4.  The Prognostic Importance of the Number of Metastatic Lymph Nodes for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiotherapy for Extrahepatic Bile Duct Cancer.

Authors:  Byoung Hyuck Kim; Kyubo Kim; Eui Kyu Chie; Jeanny Kwon; Jin-Young Jang; Sun Whe Kim; Sae-Won Han; Do-Youn Oh; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Sung W Ha
Journal:  J Gastrointest Surg       Date:  2015-08-04       Impact factor: 3.452

5.  Exosomal markers (CD63 and CD9) expression and their prognostic significance using immunohistochemistry in patients with pancreatic ductal adenocarcinoma.

Authors:  Moh'd Khushman; Girijesh Kumar Patel; Javier Ariel Laurini; Arun Bhardwaj; Kelly Roveda; Robert Donnell; Kelley Sherling; Brittany Case; Arthur E Frankel; Sachin Pai; William Taylor; Marcus Chuan Beng Tan; Meir Mizrahi; Cindy Nelson; Mary Wyatt; Mary Patton; Steven McClellan; Seema Singh; Bin Wang; Ajay P Singh
Journal:  J Gastrointest Oncol       Date:  2019-08

6.  Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma.

Authors:  Ahmed Khattab; Sunita Patruni; Stephen Abel; Shaakir Hasan; Ethan B Ludmir; Gene Finley; Dulabh Monga; Rodney E Wegner; Vivek Verma
Journal:  J Gastrointest Oncol       Date:  2019-10

7.  Lymph node ratio is an independent prognostic factor for patients after resection of pancreatic cancer.

Authors:  Han-xiang Zhan; Jian-wei Xu; Lei Wang; Guang-yong Zhang; San-yuan Hu
Journal:  World J Surg Oncol       Date:  2015-03-13       Impact factor: 2.754

Review 8.  The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma.

Authors:  Maria Diab; Irfana Muqbil; Ramzi M Mohammad; Asfar S Azmi; Philip A Philip
Journal:  J Clin Med       Date:  2016-06-16       Impact factor: 4.241

9.  Early vs. Late Chemoradiation Therapy and the Postoperative Interval to Adjuvant Therapy Do Not Correspond to Local Recurrence in Resected Pancreatic Cancer.

Authors:  Ajay A Patel; Sairaman Nagarajan; Eli D Scher; Caitlin Ab Schonewolf; Sairam Balasubramanian; Elizabeth Poplin; Rebecca Moss; David August; Darren Carpizo; Laleh Melstrom; Salma K Jabbour
Journal:  Pancreat Disord Ther       Date:  2015-04-02

10.  Identification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancer.

Authors:  Sung Hyun Kim; Ho Kyoung Hwang; Woo Jung Lee; Chang Moo Kang
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.